Red mold rice promotes neuroprotective sAPPalpha secretion instead of Alzheimer's risk factors and amyloid beta expression in hyperlipidemic Abeta40-infused rats.
Amyloid beta (Abeta) peptide is closely related to the onset of Alzheimer's disease (AD). A high-cholesterol or high-energy diet was demonstrated to stimulate Abeta formation and deposition in the amyloid precursor protein (APP) pathway and, oppositely, downregulate the secretion of the neuroprotective soluble APP alpha-fragment (sAPPalpha). Monascus-fermented red mold rice (RMR) including multiple cholesterol-lowering agents, antioxidants, and anti-inflammatory agents has been proven to ameliorate Abeta40 infusion-induced memory deficit in our previous study. In this study, the ethanol extract of RMR (RE) and natural RMR were respectively tested for their effect on the mediation of the proteolytic process of APP in cholesterol-treated human neuroblastoma IMR32 cell, as well as their effect on memory and learning ability and the expression of AD risk factors in intracerebroventricular Abeta40-infused hyperlipidemic rats. In the results, RE suppressed cholesterol-raised beta-secretase activity and further resulted in the increase of sAPPalpha secretion in the IMR32 cell. In the animal test, RMR potently reversed the memory deficit in the water maze and passive avoidance tasks. RMR administration could prevent against Abeta40 infusion plus the great damage caused by a high energy diet in hippocampus and cortex involved in the raise of thiobarbituric acid reactive substances and reactive oxygen species. The neuroprotection provided by RMR downregulates Abeta40 formation and deposition by suppressing the cholesterol-raised beta-secretase activity and apolipoprotein E expression, as well as mediates the proteolytic process of APP toward neuroprotective sAPPalpha secretion in hippocampus.
Lee
Chun-Lin
CL
Department of Life Science, National Taitung University, Taitung, Taiwan, Republic of China.
Kuo
Tzong-Fu
TF
Wu
Cheng-Lun
CL
Wang
Jyh-Jye
JJ
Pan
Tzu-Ming
TM
D000544:Alzheimer Disease / Q000453:epidemiology* / Q000473:pathology; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000627:therapeutic use; D016229:Amyloid beta-Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000473:pathology; D002552:Cerebral Ventricles; D002784:Cholesterol / Q000494:pharmacology; D005658:Fungi / Q000378:metabolism*; D006801:Humans; D006949:Hyperlipidemias / Q000378:metabolism*; D007262:Infusions, Intravenous; D007859:Learning Disabilities / Q000139:chemically induced; D008148:Lovastatin / Q000494:pharmacology; D008297:Male; D018782:Maze Learning; D008569:Memory Disorders / Q000139:chemically induced; D032741:Monascus / Q000472:pathogenicity; D012275:Oryza / Q000469:parasitology*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; D017382:Reactive Oxygen Species; D017392:Thiobarbituric Acid Reactive Substances; C078592:amyloid beta-protein (1-40); D002784:Cholesterol; D008148:Lovastatin; D053829:Amyloid Precursor Protein Secretases